SCHEMBL846130

SCHEMBL846130

O=C(Nc1nc(-c2ccco2)c(C(=O)C2CCOCC2)s1)c1ccnc(CCl)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 8/20 0.44
POLB P06746 6/20 0.43
MEN1 O00255 5/20 0.43
MAPT P10636 5/20 0.43
KMT2A Q03164 5/20 0.43
KDM4E B2RXH2 5/20 0.43
ALDH1A1 P00352 5/20 0.43
LMNA P02545 2/20 0.43
PKM P14618 2/20 0.43
HPGD P15428 4/20 0.42
BLM P54132 4/20 0.42
HSP90AA1 P07900 1/20 0.41
USP2 O75604 4/20 0.40
HSD17B10 Q99714 3/20 0.40
TDP1 Q9NUW8 3/20 0.40
PTPN7 P35236 3/20 0.40
RECQL P46063 3/20 0.40
THRB P10828 2/20 0.40
ALOX15 P16050 2/20 0.40
NR4A1 P22736 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL846336 0.89 ADORA2A (0.43) L3MBTL1POLBMEN1MAPTKMT2A
SCHEMBL1255710 0.89 L3MBTL1 (0.46) L3MBTL1POLBMEN1MAPTKMT2A
SCHEMBL846745 0.89 ROCK2 (0.47) L3MBTL1POLBMEN1MAPTKMT2A
SCHEMBL846068 0.88 KDM4E (0.42) L3MBTL1POLBMEN1MAPTKMT2A
SCHEMBL846258 0.87 L3MBTL1 (0.40) L3MBTL1POLBMEN1MAPTKMT2A
SCHEMBL1254725 0.87 L3MBTL1 (0.45) L3MBTL1POLBMEN1MAPTKMT2A
SCHEMBL879472 0.86 ADORA2A (0.40) L3MBTL1POLBMEN1MAPTKMT2A
SCHEMBL1255514 0.86 L3MBTL1 (0.46) L3MBTL1POLBMEN1MAPTKMT2A
SCHEMBL879501 0.86 KDM5C (0.44) L3MBTL1POLBMEN1MAPTKMT2A
SCHEMBL1257266 0.86 L3MBTL1 (0.48) L3MBTL1POLBMEN1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200247798-A1 THERAPEUTIC AGENT FOR ANXIETY DISORDERS KYOWA KIRIN CO LTD (JP) 2020-08-06 US disclosed
US-10407440-B2 Therapeutic agent for motor disorders KYOWA HAKKO KIRIN CO., LTD. (JP) 2019-09-10 US disclosed
EP-3378860-A1 THERAPEUTIC AGENT FOR MOTOR DISORDERS Kyowa Hakko Kirin Co., Ltd. (JP) 2018-09-26 EP disclosed
EP-2433938-B1 THERAPEUTIC AGENT FOR MOTOR DISORDERS KYOWA HAKKO KIRIN CO LTD (JP) 2018-04-18 EP disclosed
US-20170275296-A1 THERAPEUTIC AGENT FOR MOTOR DISORDERS KYOWA KIRIN CO., LTD. (JP) 2017-09-28 US disclosed
US-9714257-B2 Therapeutic agent for motor disorders KYOWA HAKKO KIRIN CO., LTD. (JP) 2017-07-25 US disclosed
EP-2474544-B1 THERAPEUTIC AGENT FOR ANXIETY DISORDERS KYOWA HAKKO KIRIN CO LTD (JP) 2017-07-12 EP disclosed
EP-2474543-B1 THERAPEUTIC AGENT FOR MOOD DISORDERS KYOWA HAKKO KIRIN CO LTD (JP) 2017-05-03 EP disclosed
US-9249135-B2 Therapeutic agent for mood disorders KYOWA HAKKO KIRIN CO., LTD. (JP) 2016-02-02 US disclosed
US-20150225417-A1 THERAPEUTIC AGENT FOR MOTOR DISORDERS KYOWA KIRIN CO., LTD. (JP) 2015-08-13 US disclosed
US-20150080415-A1 THERAPEUTIC AGENT FOR ANXIETY DISORDERS KYOWA KIRIN CO., LTD. (JP) 2015-03-19 US disclosed
US-20120184554-A1 THERAPEUTIC AGENT FOR MOOD DISORDERS KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-07-19 US disclosed
EP-2474544-A1 THERAPEUTIC AGENT FOR ANXIETY DISORDERS Kyowa Hakko Kirin Co., Ltd. (JP) 2012-07-11 EP disclosed
EP-2474543-A1 THERAPEUTIC AGENT FOR MOOD DISORDERS Kyowa Hakko Kirin Co., Ltd. (JP) 2012-07-11 EP disclosed
US-20120172362-A1 THERAPEUTIC AGENT FOR ANXIETY DISORDERS KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-07-05 US disclosed
US-20120101101-A1 THERAPEUTIC AGENT FOR MOTOR DISORDERS KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-04-26 US disclosed
EP-2433938-A1 THERAPEUTIC AGENT FOR MOTOR DISORDERS Kyowa Hakko Kirin Co., Ltd. (JP) 2012-03-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184554-A1 THERAPEUTIC AGENT FOR MOOD DISORDERS TPH1, HDAC1, HDAC2 L3MBTL1 2006/4885POLB 4565/4885MEN1 2567/4885
US-10407440-B2 Therapeutic agent for motor disorders DDT, COMT, SLC6A3 L3MBTL1 699/4885POLB 2019/4885MEN1 4731/4885
US-20170275296-A1 THERAPEUTIC AGENT FOR MOTOR DISORDERS DDT, COMT, SLC6A3 L3MBTL1 699/4885POLB 2019/4885MEN1 4731/4885
US-20120172362-A1 THERAPEUTIC AGENT FOR ANXIETY DISORDERS TAAR1, SLC6A1, GABBR1 L3MBTL1 1461/4885POLB 4607/4885MEN1 2986/4885
US-20120101101-A1 THERAPEUTIC AGENT FOR MOTOR DISORDERS DDT, COMT, SLC6A3 L3MBTL1 699/4885POLB 2019/4885MEN1 4731/4885
US-20200247798-A1 THERAPEUTIC AGENT FOR ANXIETY DISORDERS TAAR1, SLC6A1, GABBR1 L3MBTL1 1461/4885POLB 4607/4885MEN1 2986/4885
US-20150080415-A1 THERAPEUTIC AGENT FOR ANXIETY DISORDERS TAAR1, SLC6A1, GABBR1 L3MBTL1 1461/4885POLB 4607/4885MEN1 2986/4885
US-20150225417-A1 THERAPEUTIC AGENT FOR MOTOR DISORDERS DDT, COMT, SLC6A3 L3MBTL1 699/4885POLB 2019/4885MEN1 4731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.